This white paper describes new approaches to developing more effective and sustainable therapies for RA and innovative ways to conduct RA clinical trials more efficiently, successfully demonstrating value to patients and key stakeholders. 


  • Iain B. McInnes, PhD, FRSE, FMedSci, Muirhead Professor of Medicine and Director of the Institute of Infection, Immunity and Inflammation, University of Glasgow, Scotland
  • Mary Katherine (MK) Farmer, MD, Therapeutic Strategy Lead, Rheumatology, Senior Medical Director, Immunology and Internal Medicine Therapeutic Delivery Unit, Quintiles
  • Andrew Platt, PhD, Scientific Advisor, Global Central Laboratories, Quintiles